Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
AINU is set to accelerate its expansion footprint, enhance operational capabilities
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This strategic investment strengthens Cohance's integrated oligonucleotide platform
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
Currently focused on platform-related queries, elva.AI is the first step in ekincare’s broader roadmap
Subscribe To Our Newsletter & Stay Updated